Chemours price target raised to $43 from $41 at UBS

UBS analyst Joshua Spector raised the firm’s price target on Chemours to $43 from $41 and keeps a Buy rating on the shares following meetings with the company’s CEO and CFO-elect. UBS views the recent U.S. water/PFAS settlement as positive, as it quantifies what was previously a harder to define tail risk, the analyst tells investors in a research note. The firm sees progress being made on liability resolution, portfolio mix shift, and growth.